Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 14Neoplasm Metastasis 6Kidney Neoplasms 5Breast Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Glioblastoma 3Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Uveal Melanoma 1Urethral Neoplasms 1Thyroid Neoplasms 1Thymoma 1Stomach Neoplasms 1Sarcoma 1Recurrence 1Ovarian Neoplasms 1Lung Neoplasms 1Hormone Refractory Prostate Cancer 1Glioma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Fatigue 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma 1Carcinoid Tumor 1Brain Neoplasms 1

Interventions

Sunitinib 1Immunohistochemistry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Urethral Neoplasms × Sunitinib × Clear all
NCT01118039 2013-08-07

Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
41 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡